Biotech Stocks Ready To Roar
Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes.The recent uptrend
Second Half Outlook For Biotech Stocks
Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market.The direction of the 10-year
Akero Therapeutics Marching On
& Delivering Promising Results
Akero Therapeutics is making strong progress in developing a treatment for NASH, an area of high unmet medical need.The company's lead product candidate has shown promising and highly significant results
Biotech Stocks Second Quarter Outlook
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.Biotech deal-making has been increasing,
Biotechs Reel From Bank Collapse,
But Not All May Be Bad
The collapse of Silicon Valley Bank led to a market-wide selloff and caused significant volatility in biotech and technology stocks.Regulators are expected to take swift action this week to contain
Healthcare Outlook 2023
Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500.When the end to restrictive policy is in sight, then the sector is likely to
Biotech Bonanza
2023 Biotech Outlook
As The FED Remains Hawkish
Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half.Biotechs should be favorably positioned relative to the market if the economy
Biotech Stocks Well-Positioned
For The Fourth Quarter
Biotechs are relatively better positioned in this fourth quarter compared to the broader market.The path of interest rates is clearer for 2022 and the FED is closer to a pause
Healthcare Remains Steady As Market Approaches A Key Level
Healthcare Remains Steady As Market Approaches A Key LevelThe market is approaching a key technical level.Healthcare has relatively outperformed the market and has been consolidating.Biotechs found a bottom and are
What’s Next For Biotech And Healthcare
Biotechs have sold off this year along with the broader market. Declines have been more pronounced than prior pullbacks. However, healthcare continues to outperform.Federal Reserve's interest rate policy will continue
Healthcare 2022 Outlook –
An Attractive Sector In A Difficult Year
Healthcare is relatively well-positioned as a defensive sector in a volatile market environment compared to the broader market.Favorable trends to continue boosting healthcare spending.Anti-viral data to begin providing hope and
Biotech Bonanza –
2022 Biotech Outlook In A Hawkish Fed Year
Biotechs struggled in 2021 as indexes lagged the broader market.So far in 2022, biotechs have dropped sharply as interest rate uncertainty has created a risk-off market. A rising interest rate
Healthcare Marches To The Top With Opportunities for Further Gains
Healthcare had a slow start but now is one of the leading sectors in terms of 2021 performance.Healthcare is well-positioned to benefit from growing spending and pent-up demand.The sector is
The Curious Case Of Cassava Sciences
Cassava Sciences has encountered serious allegations in the citizen's petition and other discrepancies that were subsequently uncovered.The allegations do not provide a concrete and relevant connection to data manipulation.FDA will
Biotech Bonanza: Promising Second Half Outlook for Biotech Stocks
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak.The decline in biotech stocks coincided with a
Prothena: Well-Positioned In
Parkinson’s And Alzheimer’s
Prothena has developed broad expertise in removing plaques across different pathologies.FDA's acceptance of amyloid plaque reduction as a sufficient secondary endpoint for an accelerated approval de-risks multiple smallcap biotechs and
Biotechs Ready To Roar
Biotechs are ready to march forcefully higher after a lengthy consolidation.Approval of Biogen's Alzheimer's treatment delivers a bonanza for neurodegenerative-focused companies and the overall biotech sectorThe lower bar set for
Healthcare And Biotech Stocks Remain Promising With Upcoming Catalytic Decisions
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act.Biotechs face an important FDA decision on approval of an Alzheimer's treatment.Oncology companies get ready to
3 Healthcare Stocks As The Sector Breaks Out To New Highs
Healthcare has been lagging the market, but that is now changing.As biotechs consolidate, other healthcare industry groups are powering the sector to a breakout.Medical Devices and Services are poised to
3 Biotech Neurology Stocks Pursuing Alzheimer’s And Parkinson’s Diseases
Biotech stocks remain under pressure due to fear of persistently rising interest rates.Neurology is a complex area of biotech with great promise and significant challenges.New approaches are broadening out the
Healthcare Is Ready To Lead In 2021
Healthcare lagged the broader market last year, but that can change this year.A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare.Best positioned are industry groups within
Biotech Bonanza: 2021 Outlook In A Post-Pandemic Year
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market.Biotechs play a pivotal role in managing down the pandemic as vaccine
Healthcare And Biotech Outlook -Final Quarter of 2020
As the pandemic resurges, early vaccine trials are reaching the home stretch.Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments.Healthcare
Biotech Bonanza – Second Half Outlook 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed.A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates
Biotech’s Golden Moment
Biotechs are not as broadly and deeply affected by COVID-19 disruption and now lead the market as the economy begins the recovery process.Healthcare has attracted growing investor interest due to
Biotech Melt-up
A high daily death toll suggests a much more careful and measured reopening of the economy will be possible, not a quick-paced one.The pandemic thrusts the biotechnology and the pharmaceutical
Healthcare In A Bear Market
Stocks plunge into a bear market as the viral outbreak threatens to devastate the economy.Healthcare has performed relatively better than the broader market which already has plunged over 30%.The healthcare
What’s Ahead For The Stock Market
The viral outbreak is forcing the market to price a recession, although most likely it will be a transitory first-half slowdown.The US may be less prepared for the outbreak as
Biotechs Feel The Bern
Healthcare is entering a period where election cycle impact will grow. The Medicare for All healthcare plan will begin to get factored based on the success of the proponents in the
Biotech Bonanza: 2020 Outlook In An Election Year
Biotechs closed out 2019 on a strong note with the fourth quarter providing the longest sustained rally of the entire year. Favorable regulatory shifting, a timely ramp-up in M&A, FDA approvals,
4 Biotech Stocks In Neurology As Biotechs March On
Biotechs have been rejuvenated by a dose of M&A and near-term regulatory deflection After significantly lagging the broader market, biotech is steadily making progress Regulatory concerns remain
Healthcare On The March
Last week, the enormity of the risk for healthcare diminished and investors reacted favorably.Healthcare lags the broader market quite significantly, and specifically, biotechs and pharmaceuticals lag even more so.We continue
4 RNA Therapy Stocks For A Biotech Portfolio
Biotech stocks have turned the corner, moving forcefully higher, but they still have a long way to go after deeply lagging the market.The overarching systemic risk of a growing shift
Healthcare & Biotechs Struggle, But Opportunity Ahead
Healthcare has been affected by the growing thrust towards regulation to reduce costs. Biotech and pharmaceutical valuations have been hurt as efforts to control drug prices intensify. Improving risk appetite
Biotechs Second Half Battle
Biotech indexes have remained subdued as the broader market has rallied.The broader healthcare sector and biopharma industries, in particular, remain under regulatory duress just as they have been for some
Biotech Stocks Getting Ready To Explode
A dollar invested in a biotech index in 2015 would still remain a dollar in 2019 as the biotech group has been tracking sideways for 4 years.Two overarching risks have
A Biotech Friendly Event In An Unfriendly Healthcare Market
American Society of Clinical Oncology (ASCO) annual event to provide some cheer to biotechs. Healthcare remains a sector under regulatory stress and in political cross sight.Broader market buffeted by trade
3 Gene Therapy Stocks
Biotech stocks and the broader healthcare sector remain under pressure.Promising opportunities exist in the small-cap and mid-cap segments.Gene therapy remains the emerging scientific frontier in biotech.3 promising small-cap gene therapy
Healthcare And Biotechs Feel The Heat As The Market At New Highs
Market indexes have arrived at their best point since the 52-week highs set in October last year.
Enough support for the market, including nervous money on the sidelines, to
Biotech M&A Theme Builds Momentum
Biotech transaction activity continues to be sustained and well ahead of last year.
Recent industry survey indicates a strong expectation by industry insiders of future biotech M&A transactions.
A
Biotech Bonanza: The M&A Theme
Biotechs have led the V-shaped market decline and recovery over the past 2 months
A rise in M&A activity after a moribund 2018 has helped the sector to recover faster
Biotech Bonanza: 2019 Outlook
2018 was a harder year than envisioned, even though second-half turbulence was somewhat anticipated
The biotechnology sector provided opportunities for attractive returns during 2018 although the late-year decline rapidly
A Migrating Biotech Bear
Biotech sector achieves the dubious distinction of being amongst the first to slip over the Bear market threshold.
Nonetheless, this should be a transitory bear market for biotechs, as
Biotech Stocks Bloodied But Can Now Drive M&A
The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%.
The larger cap biotechs and pharmaceutical companies are performing relatively much better.
The
The Biotech Conundrum!
Biotech stocks are performing well with double-digit gains for key indexes so far in 2018.
Nonetheless, the biotech stock index returns do not appear to be favorable to the
Small Caps Are Rising. Biotech Stocks Can’t Be Far Behind!
While much attention is being riveted on the S&P 500 new all-time high eclipsing the January one, small caps accomplished that in May.
Small caps are in their next
Biotech Stocks: Tariff Safe And Building Momentum
The Nasdaq Biotechnology Index is poised to make a 52-week high and most likely an all-time high shortly thereafter.
Biotech stocks are more insulated from the biggest concern for the market
ASCO Delivers A Biotech Boost, As The Market Waits On Trump-Kim And The Fed
ASCO provides a boost to many oncology biotech stocks.
Small and midcap biotech stock index remains poised near high.
Federal Reserve to raise rates, but not deviate much from
4 Reasons & An Upcoming Catalyst to Move Biotech Stocks Higher
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
Biotechs have lagged in market performance
Biotech Stocks Emerge Unscathed And Ready To Go
The blueprint to lower drug prices leaves Biotechs unscathed and can be a net positive for the biopharma industry.
A big cloud has cleared and this will assist biotech
Biotech Stocks, Whipsawed By Volatility, Remain Well-Positioned
Biotechnology is doing what it does - being volatile. But that's normal, and the primary trend for biotechs remains positive
Industry dynamics continue to favor brighter prospects
Mergers &
Biotech Stocks Approaching New Waters
Biotech stocks are approaching highs achieved in 2015, as reflected by the Nasdaq Biotech Index.
New science is opening up great opportunities with boundless potential.
The biotech sector also
Biotech Stocks: Still Positioned For More Gains
Sharp market correction triggered by interest rate concerns creates opportunities
Market transitions into a more typical rally and pullback mode, with a continued firm uptrend
Biotech stocks are experiencing
Biotech: The Gates Begin To Open
Biotech sector starts off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A boom.
Furthermore, unlike last October, earnings season this time
2018 Outlook – Biotech Bonanza: Biotech Stocks To Keep Shining
December 20, 2017
Biotechnology delivered a solid year in 2017, overcoming the poor performance in 2016.
Multiple reasons for Biotechs to continue performing strongly in 2018.
On a relative basis,
Biotech: Opportunity Ahead!
November 30, 2017
Biotechnology sector has corrected over 10%.
Poor earnings of larger biotechs knocked the wind out of the sector.
An imminent catalyst can push the sector higher, recovering
Biotech Bonanza: A Key Piece Falls In Place!
September 07, 2017
Biotechnology begins to lead the market
Acquisition sparks a rally in biotech stocks
FDA drug approvals pick up pace
Elevated broader market risk during September and October
Biotech Bonanza: The Next Leg Up for Biotech Stocks!
July 26, 2017
FDA's new focus on accelerating drug approvals creates a valuation enhancing environment
Sentiment change with the approval of innovative life-saving drug class targeting cancer
Earnings season to
Biotech Stocks Best Chance for Breakout, Gets Even Better!
June 21, 2017
An Executive Order expected to be issued shortly clarifying health care policy.
The measures outlined are expected to be industry-friendly.
Price negotiation for Medicare is not on
Biotech’s Best Chance!
June 8, 2017
A possible "Comey Rally"
Favorable market environment for Biotechs
Positive news flow from ASCO
Potential catalysts - M&A, broader market advance, and health care policy clarity
Biotechnology
Biotech Stocks – Approaching An Inflection Point
Biotechs are performing well this year even in an uncertain environment.
Policy clarity is important and we may be approaching an inflection point.
A favorable backdrop for biotech stocks
Positives and Momentum Build for Biotechnology!
March 14, 1017
Trump nominates Scott Gottlieb for FDA Commissioner
Appears to settle debate on regulation gutting vs streamlining.
Medicare pricing negotiation appears to be not on the table.
Big
Biotech Bonanza: Breaking New Ground!
March 06, 2017
Biotechnology sector finally recorded a 52-week high, lagging the broader market by 8-months
Early stages of the rally, with multiple reasons to drive further highs in the
Biotechnology: Ready for New Highs!
February 09, 2017
Biotechs and pharmas remain under the cloud of uncertain policy
But recent developments increase confidence on the regulatory front
Sufficient biotech sector drivers now exist to create
Biotechnology: Can Trump Be A Catalyst For M&A?
January 24, 2017
Trump indicts the industry on "getting away with murder."
Pharmaceutical industry shows early signs of a shift towards self-regulation.
Innovation can be spurred by acquisitions.
Trump's activism
Biotechnology: Is 2017 A Bonanza Year?
January 11, 2017
Biotechnology sector was one of the worst performing sectors in 2016.
Political uncertainty has diminished but is still impairing investor confidence
Signs are present for the sector to
Healthcare Executives Are The Highest Paid
January 10, 2017
The Biotechnology sector's investment performance suffered last year with an over -21% decline. But don't let that dissuade you from joining drugmaker companies. According to a recent Bloomberg Pay
Biotechnology Stocks Struck By Bolt From Trump Tower
December 08, 2017
The pharmaceuticals and biotechnology stocks retreated sharply today, as Trump was quoted in a Time magazine "Person of the Year" article as being upset about the high drug prices
Biotech Bonanza – 5 Reasons For Biotech Stocks To Shine. 2017 Outlook
The pendulum has swung in the other direction, and Biotechnology is poised to become a leading sector heading into 2017
The diminished risk of policy uncertainty positions the biotech sector
Biotech Stocks Overreact, Fearing An Election “Sweep”
Sharp decline in Biotech Stocks last week was a reaction to political winds.
Biotechs fear an election sweep giving control of Congress and White House to a single-party.
We
Yellen & Clinton Combo To Take Stock Market Higher
SEPTEMBER 29, 2016
Chair Janet Yellen delivers an unchanged monetary policy soothing the market.
Hillary Clinton appears to regain her footing in the presidential elections soothing global markets.
Technology earnings
Biotech Stocks: No Easy Way Out, But Almost There!
SEPTEMBER 15, 2016
Difficult year for Biotech stocks so far with the sector down -17% YTD
Fundamentally the biotech sector is gaining strength
Meaningful policy clarity to be achieved in
Is Biotechnology Finally Ready To Move Higher?
JULY 25, 2016
Broader market rally to new highs has raised the probability of a Biotechnology breakout.
After a nearly 6-month trading range consolidation, the sector appears poised to make
Biotechnology – The Perfect Yo-Yo
JULY 06, 2016
The Biotechnology Sector Has Been Range-bound this year.
Conditions for a move higher were optimal, till Brexit happened.
The generally positive stock market backdrop can help the
Brexit Doesn’t Mean An Exit On Stocks
June 30, 2016
One thing that became certain after the British referendum favoring an Exit from the Eurozone, popularly referred to as Brexit for "British Exit," is a shifting of the
Biotechnology: Clearer Skies, Ready To Move Higher
JUNE 03, 2016
The biotech sector is well-positioned to move higher now than at any other time this year
Consolidation activity has begin to forcefully rise which has spurred investor
Biotechnology: Entering A Pocket Of Turbulence
The biotechnology sector performed strongly during March and April.
Some sector-specific and market-related factors are clouding the positive narrative of the Biotechnology sector.
Even though near-term caution is advisable,
The Thundering Quant Bulls
APRILÂ 21, 2016
Yesterday, April 20, the S&P500 reached a critical stock market technical level of 2100. This is the level around which the index had peaked in November 2015.
Why is this
Our Investing Biases Cost Us Investment Returns!
APRIL 07, 2016
We are influenced by the pool of emotions and experiences accumulated over our lifetime, which create certain preferences or proclivities in our thinking. We lean on these tendencies, when making
Biotechnology Stocks Poised To Move Higher!
MARCH 28, 2016
The Biotechnology sector has not participated in the recent market rise for reasons which are losing their grip
We believe the process of bottoming out has occurred,
It’s The Fed’s Move Once Again!
Stock Market Outlook
MARCH 15, 2016
Federal Reserve will update its “dot plot” to reflect the median rate hikes for 2016, and that number is widely expected to come down to 3 from 4
A more
Is The Biotech Sector Bottoming Out?
FEBRUARY 01, 2016
Biotech sector has corrected 35% since its peak in July 2015
Worst appears to be over and we are close to a Biotech bottom, if not there yet
More consolidation
Don’t Go Chasing The Market Lows!
JANUARY 15, 2016
Don’t Go Chasing Market Lows … they just keep getting lower!
Biotechs represent a sector with tremendous potential. At the same time, it’s a highly volatile sector and quite
The Fed’s Done For Now – Stock Market And Small Cap Viewpoint For 2016
JANUARY 07, 2016
We anticipate the market decline to provide fresh legs for a new rally later in the first quarter and early second quarter.
For the year, we anticipate a positive
Biotech Stocks Can’t Be Ignored!
DECEMBER 2015
Biotech is a sector that has outperformed the market meaningfully over a market cycle
The general perception of the sector being highly risky overlooks a portfolio approach as well as